Скачать с ютуб The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL в хорошем качестве

The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL

Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, shares insights into the effectiveness of ibrutinib flexible dosing treatment strategies on the time to next treatment (TTNT) for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This real-world data study on over 3000 patients showed that dose adjustment of ibrutinib was not associated with an increased risk of initiating the next line of therapy (LOT) when compared with continuous standard dosing. This suggests that a flexible dosing approach may be used to increase the safety of treatment whilst maintaining its efficacy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.